The UK Health Security Agency (UKHSA) has reported that COVID hospitalizations in Britain are experiencing a sharp increase due to a new variant. Recent statistics show that the admission rate for patients with the COVID XEC variant climbed to 4.5 per 100,000 people in the week ending October 6, from 3.7 the previous week.
First identified in Germany in June, the XEC variant has appeared in several countries, including the United States and Denmark. This variant is a hybrid of the KS.1.1 and KP.3.3 variants and exhibits common Covid symptoms like fatigue, headaches, sore throats, and high temperatures.
Experts note that the XEC, part of the omicron subfamily, responds well to current vaccines and boosters, crucial in preventing severe illness and hospitalization.
This variant shows particular mutations in the spike protein, crucial for the virus’s ability to bind to human cells. These mutations include a change from phenylalanine (F) to leucine (L) and from arginine (R) to threonine (T). The KP.3.3 subvariant, falling under the FLuQE category, features a significant mutation where glutamine (Q) changes to glutamic acid (E), potentially increasing its ability to bind to human cells.
The US Centers for Disease Control and Prevention recommend maintaining robust hygiene practices and enhancing indoor air quality. Symptoms of the Covid XEC variant are similar to other strains, including:
- High temperature
- Aches
- Tiredness
- Cough or sore throat
Although some individuals may experience extended symptoms, the recovery typically occurs within a few weeks.
The NHS has initiated an autumn booster campaign targeting vulnerable populations. Eligibility for the booster includes:
- Individuals over 65
- People from six months to 64 years with specific health conditions, including pregnant women
- Residents in care homes for the elderly
- Frontline NHS and social care staff
